PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)

por Hamadani, M., Linhares, Y., Gandhi, M. D., Chung, M., Adamis, H., Ungar, D., Carlo-Stella, C., Kingsley, E., Depaus, J., Snauwaert, S., Kwiatek, M., López-Jiménez, J.
Publicado 2022

P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE

por Vekemans, M-C, Delforge, M, Anguille, S, Depaus, J, Meuleman, N, Van de Velde, A, Vande Broek, I, Strens, D, Van Hoorenbeeck, S, Moorkens, EJ, Diels, J, Ghilotti, F, Dalhuisen, S, Vandervennet, S
Publicado 2022